Tim Wilsdon moderates the session discussing how to fast-track policy solutions that could address the barriers preventing patient access to NGS and identify the ones that should be prioritized.
For more information on this event, click here.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...